Noonan syndrome (NS) is a relatively common, clinically variable and genetically heterogeneous developmental disorder characterized by postnatally reduced growth, distinctive facial dysmorphism, cardiac defects and variable cognitive deficits. Other associated features include ectodermal and skeletal defects, cryptorchidism, lymphatic dysplasias, bleeding tendency, and, rarely, predisposition to hematologic malignancies during childhood. NS is caused by mutations in the PTPN11, SOS1, KRAS, RAF1, BRAF and MEK1 (MAP2K1) genes, accounting for approximately 70% of affected individuals. SHP2 (encoded by PTPN11), SOS1, BRAF, RAF1 and MEK1 positively contribute to RAS-MAPK signaling, and possess complex autoinhibitory mechanisms that are impaired by mutations. Similarly, reduced GTPase activity or increased guanine nucleotide release underlie the aberrant signal flow through the MAPK cascade promoted by most KRAS mutations. More recently, a single missense mutation in SHOC2, which encodes a cytoplasmic scaffold positively controlling RAF1 activation, has been discovered to cause a closely related phenotype previously termed Noonan-like syndrome with loose anagen hair. This mutation promotes aberrantly acquired N-myristoylation of the protein, resulting in its constitutive targeting to the plasma membrane and dysregulated function. PTPN11, BRAF and RAF1 mutations also account for approximately 95% of LEOPARD syndrome, a condition which resembles NS phenotypically but is characterized by multiple lentigines dispersed throughout the body, café-au-lait spots, and a higher prevalence of electrocardiographic conduction abnormalities, obstructive cardiomyopathy and sensorineural hearing deficits. These recent discoveries demonstrate that the substantial phenotypic variation characterizing NS and related conditions can be ascribed, in part, to the gene mutated and even the specific molecular lesion involved.

Keywords:
Cardiofaciocutaneous syndrome, Costello syndrome, Genotype-phenotype correlations, LEOPARD syndrome, Molecular basis of disease, Molecular epidemiology, Mutation analysis, Neurocardiofacialcutaneous syndrome family, Noonan syndrome, RAS signaling
1.
Adekunle O, Gopee A, el-Sayed M, Thilaganathan B: Increased first trimester nuchal translucency: Pregnancy and infant outcomes after routine screening for Down’s syndrome in an unselected antenatal population. Br J Radiol 72:457–460 (1999).
2.
Adjei AA: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93:1062–1074 (2001).
3.
Ahmed ML, Foot AB, Edge JA, Lamkin VA, Savage MO, Dunger DB: Noonan’s syndrome: Abnormalities of the growth hormone/IGF axis and the response to treatment with human biosynthetic growth hormone. Acta Paediatr Scand 80:446–450 (1991).
4.
Alfieri P, Cesarini L, Zampino G, Pantaleoni F, Selicorni A, et al: Visual function in Noonan and LEOPARD syndrome. Neuropediatrics 39:335–340 (2008).
5.
Allanson JE: Noonan syndrome. Am J Med Genet C Semin Med Genet 145C:274–279 (2007).
6.
Allanson JE, Hall JG, Hughes HE, Preus M, Witt RD: Noonan syndrome: The changing phenotype. Am J Med Genet 21:507–514 (1985a).
7.
Allanson JE, Hall JG, Van Allen MI: Noonan phenotype associated with neurofibromatosis. Am J Med Genet 21:457–462 (1985b).
8.
Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, et al: Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 37:1038–1040 (2005).
9.
Armour CM, Allanson JE: Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations. J Med Genet 45:249–254 (2008).
10.
Bader-Meunier B, Tchernia G, Mielot F, Fontaine JL, Thomas C, et al: Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr 130:885–889 (1997).
11.
Baltaxe HA, Lee JG, Ehlers KH, Engle MA: Pulmonary lymphangiectasia demonstrated by lymphangiography in 2 patients with Noonan’s syndrome. Radiology 115:149–153 (1975).
12.
Baralle D, Mattocks C, Kalidas K, Elmslie F, Whittaker J, et al: Different mutations in the NF1 gene are associated with neurofibromatosis-Noonan syndrome (NFNS). Am J Med Genet 119A:1–8 (2003).
13.
Barbacid M: Ras genes. Annu Rev Biochem 56:779–827 (1987).
14.
Bélanger LF, Roy S, Tremblay M, Brott B, Steff AM, et al: Mek2 is dispensable for mouse growth and development. Mol Cell Biol 23:4778–4787 (2003).
15.
Beneteau C, Cavé H, Moncla A, Dorison N, Munnich A, et al: SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions. Eur J Hum Genet 17:1216–1221 (2009).
16.
Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, et al: Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64:8816–8820 (2004).
17.
Bertola DR, Kim CA, Sugayama SM, Albano LM, Wagenfuhr J, et al: Cardiac findings in 31 patients with Noonan’s syndrome. Arq Bras Cardiol 75:409–412 (2000).
18.
Bertola DR, Pereira AC, Passetti F, de Oliveira PS, Messiaen L, et al: Neurofibromatosis-Noonan syndrome: Molecular evidence of the concurrence of both disorders in a patient. Am J Med Genet A 136:242–245 (2005).
19.
Binder G, Neuer K, Ranke MB, Wittekindt NE: PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab 90:5377–5381 (2005).
20.
Bos JL: Ras oncogenes in human cancer: a review. Cancer Res 49:4682–4689 (1989).
21.
Boutin JA: Myristoylation. Cell Signal 9:15–35 (1997).
22.
Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, et al: Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 39:1120–1126 (2007).
23.
Brown DC, Macfarlane CE, McKenna WJ, Patton MA, Dunger DB, et al: Growth hormone therapy in Noonan’s syndrome: Non-cardiomyopathic congenital heart disease does not adversely affect growth improvement. J Pediatr Endocrinol Metab 15:851–852 (2002).
24.
Burch M, Sharland M, Shinebourne E, Smith G, Patton M, McKenna W: Cardiologic abnormalities in Noonan syndrome: Phenotypic diagnosis and echocardiographic assessment of 118 patients. J Am Coll Cardiol 22:1189–1192 (1993).
25.
Carey JC: Neurofibromatosis-Noonan syndrome. Am J Med Genet 75:263–264 (1998).
26.
Carta C, Pantaleoni F, Bocchinfuso G, Stella L, Vasta I, et al: Germline missense mutations affecting KRAS isoform b are associated with a severe Noonan syndrome phenotype. Am J Hum Genet 79:129–135 (2006).
27.
Cesarini L, Alfieri P, Pantaleoni F, Vasta I, Cerutti M, et al: Cognitive profile of disorders associated with dysregulation of the RAS/MAPK signaling cascade. Am J Med Genet 149A:140–146 (2009).
28.
Chan RJ, Leedy MB, Munugalavadla V, Voorhorst CS, Li Y, et al: Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Blood 105:3737–3742 (2005).
29.
Chardin P, Camonis JH, Gale NW, van Aelst L, Schlessinger J, et al: Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science 260:1338–1343 (1993).
30.
Chen RH, Corbalan-Garcia S, Bar-Sagi D: The role of the PH domain in the signal-dependent membrane targeting of Sos. EMBO J 16:1351–1359 (1997).
31.
Chen Y, Takita J, Hiwatari M, Igarashi T, Hanada R, et al: Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes Cancer 45:583–591 (2006).
32.
Choong K, Freedman MH, Chitayat D, Kelly EN, Taylor G, Zipursky A: Juvenile myelomonocytic leukemia and Noonan syndrome. J Pediatr Hematol Oncol 21:523–527 (1999).
33.
Clanton DJ, Hattori S, Shih TY: Mutations of the Ras gene product p21 that abolish guanine nucleotide binding. Proc Natl Acad Sci USA 83:5076–5080 (1986).
34.
Cohen MM Jr, Gorlin RJ: Noonan-like/multiple giant cell lesion syndrome. Am J Med Genet 40:159–166 (1991).
35.
Colby WW, Hayflick JS, Clark SG, Levinson AD: Biochemical characterization of polypeptides encoded by mutated human Ha-ras1 genes. Mol Cell Biol 6:730–734 (1986).
36.
Cordeddu V, Di Schiavi E, Pennacchio LA, Ma’ayan A, Sarkozy A, et al: Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet 41:1022–1026 (2009).
37.
Costello JM: A new syndrome. NZ Med J 74:397 (1971).
38.
Costello JM: A new syndrome: mental subnormality and nasal papillomata. Aust Paediatr J 13:114–118 (1977).
39.
Cotterill AM, McKenna WJ, Brady AF, Sharland M, Elsawi M, et al: The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan’s syndrome. J Clin Endocrinol Metab 81:2291–2297 (1996).
40.
Cowley S, Paterson H, Kemp P, Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77:841–852 (1994).
41.
Cremers CW, van der Burgt CJ: Hearing loss in Noonan syndrome. Int J Pediatr Otorhinolaryngol 23:81–84 (1992).
42.
Dance M, Montagner A, Salles JP, Yart A, Raynal P: The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal 20:453–459 (2008).
43.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al: Mutations of the BRAF gene in human cancer. Nature 417:949–954 (2002).
44.
De Luca A, Bottillo I, Sarkozy A, Carta C, Neri C, et al: NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. Am J Hum Genet 77:1092–1101 (2005).
45.
Denayer E, Parret A, Chmara M, Schubbert S, Vogels A, et al: Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Hum Mutat 29:232–239 (2008).
46.
Dentici ML, Sarkozy A, Pantaleoni F, Carta C, Lepri F, et al: Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations. Eur J Hum Genet 17:733–740 (2009).
47.
Der CJ, Pan BT, Cooper GM: RasH mutants deficient in GTP binding. Mol Cell Biol 6:3291–3294 (1986).
48.
Dhomen N, Marais R: New insight into BRAF mutations in cancer. Curr Opin Genet Dev 17:31–39 (2007).
49.
Digilio MC, Conti E, Sarkozy A, Mingarelli R, Dottorini T, et al: Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 71:389–394 (2002).
50.
Digilio MC, Sarkozy A, de Zorzi A, Pacileo G, Limongelli G, et al: LEOPARD syndrome: clinical diagnosis in the first year of life. Am J Med Genet A 140A:740–674 (2006).
51.
Duncan WJ, Fowler RS, Farkas LG, Ross RB, Wright AW, et al: A comprehensive scoring system for evaluating Noonan syndrome. Am J Med Genet 10:37–50 (1981).
52.
Emuss V, Garnett M, Mason C, Marais R: Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res 65:9719–9726 (2005).
53.
Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA: HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A 140:8–16 (2006).
54.
Farazi TA, Waksman G, Gordon JI: The biology and enzymology of protein N-myristoylation. J Biol Chem 276:39501–39504 (2001).
55.
Feig LA, Pan BT, Roberts TM, Cooper GM: Isolation of Ras GTP-binding mutants using an in situ colony-binding assay. Proc Natl Acad Sci USA 83:4607–4611 (1986).
56.
Ferreira LV, Souza SA, Arnhold IJ, Mendonca BB, Jorge AA: PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome. J Clin Endocrinol Metab 90:5156–5160 (2005).
57.
Fisher E, Weiss EB, Michals K, DuBrow IW, Hastrieter AR, Matalon R: Spontaneous chylothorax in Noonan’s syndrome. Eur J Pediatr 138:282–284 (1982).
58.
Friday BB, Adjei AA: K-ras as a target for cancer therapy. Biochim Biophys Acta 1756:127–144 (2005).
59.
Fryer AE, Holt PJ, Hughes HE: The cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome: Are they the same? Am J Med Genet 38:548–551 (1991).
60.
Fukuda M, Horibe K, Miyajima Y, Matsumoto K, Nagashima M: Spontaneous remission of juvenile chronic myelomonocytic leukemia in an infant with Noonan syndrome. J Pediatr Hematol Oncol 19:177–179 (1997).
61.
George CD, Patton MA, el Sawi M, Sharland M, Adam EJ: Abdominal ultrasound in Noonan syndrome: A study of 44 patients. Pediatr Radiol 23:316–318 (1993).
62.
Giroux S, Tremblay M, Bernard D, Cardin-Girard JF, Aubry S, et al: Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr Biol 9:369–372 (1999).
63.
Gorlin RJ, Anderson RC, Moller JH: The leopard (multiple lentigines) syndrome revisited. Birth Defects Orig Artic Ser 7:110–115 (1971).
64.
Gorlin JR, Cohen MM, Levin LS: Leopard syndrome; in Gorlin JR, Cohen MM, Levin LS (eds): Syndromes of the Head and Neck, pp 461–464 (Oxford University Press, New York 1990).
65.
Graham JM Jr, Kramer N, Bejjani BA, Thiel CT, Carta C, et al: Genomic duplication of PTPN11 is an uncommon cause of Noonan syndrome. Am J Med Genet A 149A:2122–2128 (2009).
66.
Gripp KW: Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet 137C:72–77 (2005).
67.
Gripp KW, Lin AE, Stabley DL, Nicholson L, Scott CI Jr, et al: HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A 140A:1–7 (2006).
68.
Hanna N, Montagner A, Lee WH, Miteva M, Vidal M, et al: Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1. FEBS Lett 580:2477–2482 (2006).
69.
Hanna N, Parfait B, Talaat IM, Vidaud M, Elsedfy HH: SOS1: a new player in the Noonan-like/multiple giant cell lesion syndrome. Clin Genet 75:568–571 (2009).
70.
Hennekam RC: Costello syndrome: an overview. Am J Med Genet C Semin Med Genet 117C:42–48 (2003).
71.
Hernandez RJ, Stern AM, Rosenthal A: Pulmonary lymphangiectasis in Noonan syndrome. AJR Am J Roentgenol 134:75–80 (1980).
72.
Herzog DB, Logan R, Kooistra JB: The Noonan syndrome with intestinal lymphangiectasia. J Pediatr 88:270–272 (1976).
73.
Hiippala A, Eronen M, Taipale P, Salonen R, Hiilesmaa V: Fetal nuchal translucency and normal chromosomes: A long-term follow-up study. Ultrasound Obstet Gynecol 18:18–22 (2001).
74.
Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE: Crystal structure of the tyrosine phosphatase SHP-2. Cell 92:441–450 (1998).
75.
Hüffmeier U, Zenker M, Hoyer J, Fahsold R, Rauch A: A variable combination of features of Noonan syndrome and neurofibromatosis type I are caused by mutations in the NF1 gene. Am J Med Genet A 140A:2749–2756 (2006).
76.
Hugues L, Cavé H, Philippe N, Pereira S, Fenaux P, Preudhomme C: Mutations of PTPN11 are rare in adult myeloid malignancies. Haematologica 90:853–854 (2005).
77.
Jafarov T, Ferimazova N, Reichenberger E: Noonan-like syndrome mutations in PTPN11 in patients diagnosed with cherubism. Clin Genet 68:190–191 (2005).
78.
Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, et al: K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev 11:2468–2481 (1997).
79.
Jongmans M, Sistermans EA, Rikken A, Nillesen WM, Tamminga R, et al: Genotypic and phenotypic characterization of Noonan syndrome: New data and review of the literature. Am J Med Genet A 134A:165–170 (2005).
80.
Keilhack H, David FS, McGregor M, Cantley LC, Neel BG: Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem 280:30984–30993 (2005).
81.
Kerr B, Delrue MA, Sigaudy S, Perveen R, Marche M, et al: Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J Med Genet 43:401–405 (2006).
82.
Koera K, Nakamura K, Nakao K, Miyoshi J, Toyoshima K, et al: K-ras is essential for the development of the mouse embryo. Oncogene 15:1151–1159 (1997).
83.
Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG: PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem 281:6785–6792 (2006).
84.
Koudova M, Seemanova E, Zenker M: Novel BRAF mutation in a patient with LEOPARD syndrome and normal intelligence. Eur J Med Genet 52:337–340 (2009).
85.
Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergsträsser E, et al: The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 106:2183–2185 (2005).
86.
Kratz CP, Niemeyer CM, Thomas C, Bauhuber S, Matejas V, et al: Mutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia. Leukemia 21:1108–1109 (2007).
87.
Kratz CP, Zampino G, Kriek M, Kant SG, Leoni C, et al: Craniosynostosis in patients with Noonan syndrome caused by germline KRAS mutations. Am J Med Genet A 149A:1036–1040 (2009).
88.
Lanning P, Simila S, Suramo I, Paavilainen T: Lymphatic abnormalities in Noonan’s syndrome. Pediatr Radiol 7:106–109 (1978).
89.
Lee JC, Tartaglia M, Gelb BD, Fridrich K, Sachs S, et al: Phenotypic and genotypic characterization of Noonan-like/multiple giant cell lesion syndrome. J Med Genet 42:e11 (2005).
90.
Lee KA, Williams B, Roza K, Ferguson H, David K, et al: PTPN11 analysis for the prenatal diagnosis of Noonan syndrome in fetuses with abnormal ultrasound findings. Clin Genet 75:190–194 (2009).
91.
Lee NB, Kelly L, Sharland M: Ocular manifestations of Noonan syndrome. Eye 6:328–334 (1992).
92.
Legius E, Schrander-Stumpel C, Schollen E, Pulles-Heintzberger C, Gewillig M, Fryns JP: PTPN11 mutations in LEOPARD syndrome. J Med Genet 39:571–574 (2002).
93.
Leicht DT, Balan V, Kaplun A, Singh-Gupta V, Kaplun L, et al: Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta 1773:1196–1212 (2007).
94.
Loh ML, Reynolds MG, Vattikuti S, Gerbing RB, Alonzo TA, et al: PTPN11 mutations in pediatric patients with acute myeloid leukemia: Results from the children’s cancer group. Leukemia 18:1831–1834 (2004a).
95.
Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, et al: Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103:2325–2331 (2004b).
96.
Loh ML, Martinelli S, Cordeddu V, Reynolds MG, Vattikuti S, et al: Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Res 29:459–462 (2005).
97.
MacFarlane CE, Brown DC, Johnston LB, Patton MA, Dunger DB, et al: Growth hormone therapy and growth in children with Noonan’s syndrome: Results of 3 years’ follow-up. J Clin Endocrinol Metab 86:1953–1956 (2001).
98.
Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, et al: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265:966–970 (1994).
99.
Marcus KA, Sweep CG, van der Burgt I, Noordam C: Impaired Sertoli cell function in males diagnosed with Noonan syndrome. J Pediatr Endocrinol Metab 21:1079–1084 (2008).
100.
Margarit SM, Sondermann H, Hall BE, Nagar B, Hoelz A, et al: Structural evidence for feedback activation by Ras.GTP of the Ras-specific nucleotide exchange factor SOS. Cell 112:685–695 (2003).
101.
Marino B, Digilio MC, Toscano A, Giannotti A, Dallapiccola B: Congenital heart diseases in children with Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr 135:703–706 (1999).
102.
Martinelli S, Carta C, Flex E, Binni F, Cordisco EL, et al: Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. Cancer Genet Cytogenet 166:124–129 (2006).
103.
Martinelli S, Torreri P, Tinti M, Stella L, Bocchinfuso G, et al: Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes. Hum Mol Genet 17:2018–2029 (2008).
104.
Martinelli S, McDowell HP, Vigne SD, Kokai G, Uccini S, et al: RAS signaling dysregulation in human embryonal rhabdomyosarcoma. Genes Chromosomes Cancer 48:975–982 (2009).
105.
Mascheroni E, Digilio MC, Cortis E, Devito R, Sarkozy A, et al: Pigmented villonodular synovitis in a patient with Noonan syndrome and SOS1 gene mutation. Am J Med Genet A 146A:2966–2967 (2008).
106.
Massarano AA, Wood A, Tait RC, Stevens R, Super M: Noonan syndrome: Coagulation and clinical aspects. Acta Paediatr 85:1181–1185 (1996).
107.
Mazzanti L, Cacciari E, Cicognani A, Bergamaschi R, Scarano E, Forabosco A:Noonan-like syndrome with loose anagen hair: a new syndrome? Am J Med Genet A 118A:279–286 (2003).
108.
Mikula M, Schreiber M, Husak Z, Kucerova L, Rüth J, et al: Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J 20:1952–1962 (2001).
109.
Mitin N, Rossman KL, Der CJ: Signaling interplay in Ras superfamily function. Curr Biol 15:R563–R574 (2005).
110.
Naficy S, Shepard NT, Telian SA: Multiple temporal bone anomalies associated with Noonan syndrome. Otolaryngol Head Neck Surg 116:265–267 (1997).
111.
Narumi Y, Aoki Y, Niihori T, Neri G, Cavé H, et al: Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome. Am J Med Genet A 143A:799–807 (2007).
112.
Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, et al: Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet 44:763–771 (2007).
113.
Neel BG, Gu H, Pao L: The ‘Shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28:284–293 (2003).
114.
Neri G, Zollino M, Reynolds JF: The Noonan-CFC controversy. Am J Med Genet 39:367–370 (1991).
115.
Neumann TE, Allanson J, Kavamura I, Kerr B, Neri G, et al: Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome. Eur J Hum Genet 17:420–425 (2009).
116.
Niemeyer CM, Kratz CP: Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br J Haematol 140:610–624 (2008).
117.
Niihori T, Aoki Y, Narumi Y, Neri G, Cavé H, et al: Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38:294–296 (2006).
118.
Nimnual A, Bar-Sagi D: The two hats of SOS. Sci STKE 145:PE36 (2002).
119.
Nimnual AS, Yatsula BA, Bar-Sagi D: Coupling of Ras and Rac guanosine triphosphatases through the Ras exchanger Sos. Science 279:560–563 (1998).
120.
Nisbet DL, Griffin DR, Chitty LS: Prenatal features of Noonan syndrome. Prenat Diagn 19:642–647 (1999).
121.
Noonan JA: Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child 116:373–380 (1968).
122.
Noonan JA: Noonan syndrome. An update and review for the primary pediatrician. Clin Pediatr (Phila) 33:548–555 (1994).
123.
Noordam C, Draaisma JM, van den Nieuwenhof J, van der Burgt I, Otten BJ, Daniels O: Effects of growth hormone treatment on left ventricular dimensions in children with Noonan’s syndrome. Horm Res 56:110–113 (2001).
124.
Noordam C, Peer PG, Francois I, De Schepper J, van den Burgt I, Otten BJ: Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11. Eur J Endocrinol 159:203–208 (2008).
125.
Noordam K, van der Burgt I, Brunner HG, Otten BJ: The relationship between clinical severity of Noonan’s syndrome and growth, growth hormone (GH) secretion and response to GH treatment. JPediatr Endocrinol Metab 15:175–180 (2002).
126.
Nora JJ, Nora AH, Sinha AK, Spangler RD, Lubs HA: The Ullrich-Noonan syndrome (Turner phenotype). Am J Dis Child 127:48–55 (1974).
127.
Nyström AM, Ekvall S, Berglund E, Björkqvist M, Braathen G, et al: Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders. J Med Genet 45:500–506 (2008).
128.
Nyström AM, Ekvall S, Allanson J, Edeby C, Elinder M, et al: Noonan syndrome and neurofibromatosis type I in a family with a novel mutation in NF1. Clin Genet 76:524–534 (2009).
129.
Oishi K, Zhang H, Gault WJ, Wang CJ, Tan CC, et al: Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development. Hum Mol Genet 18:193–201 (2009).
130.
Opitz JM, Weaver DD: The neurofibromatosis-Noonan syndrome. Am J Med Genet 21:477–490 (1985).
131.
Ozturk S, Cefle K, Palanduz S, Erten NB, Karan MA, et al: A case of Noonan syndrome with pulmonary and abdominal lymphangiectasia. Int J Clin Pract 54:274–276 (2000).
132.
Padidela R, Camacho-Hübner C, Attie KM, Savage MO: Abnormal growth in Noonan syndrome: genetic and endocrine features and optimal treatment. Horm Res 70:129–136 (2008).
133.
Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, et al: Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 39:1007–1012 (2007).
134.
Pasmant E, Sabbagh A, Hanna N, Masliah-Planchon J, Jolly E, et al: SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J Med Genet 46:425–430 (2009).
135.
Pierpont EI, Pierpont ME, Mendelsohn NJ, Roberts AE, Tworog-Dube E, Seidenberg MS: Genotype differences in cognitive functioning in Noonan syndrome. Genes Brain Behav 8:275–282 (2009).
136.
Plowman SJ, Williamson DJ, O’Sullivan MJ, Doig J, Ritchie AM, et al: While K-ras is essential for mouse development, expression of the K-ras 4a splice variant is dispensable. Mol Cell Biol 23:9245–9250 (2003).
137.
Pritchard CA, Bolin L, Slattery R, Murray R, McMahon M: Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene. Curr Biol 6:614–617 (1996).
138.
Qiu WW, Yin SS, Stucker FJ: Audiologic manifestations of Noonan syndrome. Otolaryngol Head Neck Surg 118:319–323 (1998).
139.
Quilliam LA, Khosravi-Far R, Huff SY, Der CJ: Guanine nucleotide exchange factors: activators of the Ras superfamily of proteins. Bioessays 17:395–404 (1995).
140.
Quilliam LA, Rebhun JF, Castro AF: A growing family of guanine nucleotide exchange factors is responsible for activation of Ras-family GTPases. Prog Nucleic Acid Res Mol Biol 71:391–444 (2002).
141.
Rajalingam K, Schreck R, Rapp UR, Albert S: Ras oncogenes and their downstream targets. Bioch Biophys Acta 1773:1177–1195 (2007).
142.
Ranke MB, Heidemann P, Knupfer C, Enders H, Schmaltz AA, Bierich JR: Noonan syndrome: Growth and clinical manifestations in 144 cases. Eur J Pediatr 148:220–227 (1988).
143.
Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, et al: Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 39:1013–1017 (2007).
144.
Resh MD: Trafficking and signaling by fatty-acylated and prenylated proteins. Nat Chem Biol 2:584–590 (2006).
145.
Reynders CS, Pauker SP, Benacerraf BR: First trimester isolated fetal nuchal lucency: Significance and outcome. J Ultrasound Med 16:101–105 (1997).
146.
Reynolds JF, Neri G, Herrmann JP, Blumberg B, Coldwell JG, et al: New multiple congenital anomalies/mental retardation syndrome with cardio-facio-cutaneous involvement – the CFC syndrome. Am J Med Genet 25:413–427 (1986).
147.
Roberts A, Allanson J, Jadico SK, Kavamura MI, Noonan J, et al: The cardiofaciocutaneous syndrome. J Med Genet 43:833–842 (2006).
148.
Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, et al: Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 39:70–74 (2007).
149.
Rodriguez-Viciana P, Oses-Prieto J, Burlinqame A, Fried M, McCormick F: A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Mol Cell 22:217–230 (2006a).
150.
Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, et al: Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311:1287–1290 (2006b).
151.
Romano AA, Dana K, Bakker B, Davis DA, Hunold JJ, et al: Growth response, near-adult height, and patterns of growth and puberty in patients with Noonan syndrome treated with growth hormone. J Clin Endocrinol Metab 94:2338–2344 (2009).
152.
Sarkozy A, Obregon MG, Conti E, Esposito G, Mingarelli R, et al: A novel PTPN11 gene mutation bridges Noonan syndrome, multiple lentigines/LEOPARD syndrome and Noonan-like/multiple giant cell lesion syndrome. Eur J Hum Genet 12:1069–1072 (2004).
153.
Sarkozy A, Carta C, Moretti S, Zampino G, Digilio MC, et al: Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat 30:695–702 (2009a).
154.
Sarkozy A, Digilio MC, Zampino G, Dallapiccola D, Tartaglia M, Gelb BD: LEOPARD syndrome: clinical aspects and molecular pathogenesis; in Zenker M (ed): Noonan Syndrome and Related Disorders. Monogr Hum Genet 17:55–65 (Karger, Basel 2009b).
155.
Schreck R, Rapp UR: Raf kinases: oncogenesis and drug discovery. Int J Cancer 119:2261–2271 (2006).
156.
Schubbert S, Lieuw K, Rowe SL, Lee CM, Li X, et al: Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 106:311–317 (2005).
157.
Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, et al: Germline KRAS mutations cause Noonan syndrome. Nat Genet 38:331–336 (2006).
158.
Schubbert S, Bollag G, Lyubynska N, Nguyen H, Kratz CP, et al: Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol 27:7765–7770 (2007a).
159.
Schubbert S, Shannon K, Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295–308 (2007b).
160.
Schulz AL, Albrecht B, Arici C, van der Burgt I, Buske A, et al: Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome. Clin Genet 73:62–70 (2008).
161.
Seeburg PH, Colby WW, Capon DJ, Goeddel DV, Levinson AD: Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 312:71–75 (1984).
162.
Selfors LM, Schutzman JL, Borland CZ, Stern MJ: Soc-2 encodes a leucine-rich repeat protein implicated in fibroblast growth factor receptor signaling. Proc Natl Acad Sci USA 95:6903–6908 (1998).
163.
Shah N, Rodriguez M, Louis DS, Lindley K, Milla PJ: Feeding difficulties and foregut dysmotility in Noonan’s syndrome. Arch Dis Child 81:28–31 (1999).
164.
Sharland M, Burch M, McKenna WM, Patton MA: A clinical study of Noonan syndrome. Arch Dis Child 67:178–183 (1992a).
165.
Sharland M, Patton MA, Talbot S, Chitolie A, Bevan DH: Coagulation-factor deficiencies and abnormal bleeding in Noonan’s syndrome. Lancet 339:19–21 (1992b).
166.
Shchelochkov OA, Patel A, Weissenberger GM, Chinault AC, Wiszniewska J, et al: Duplication of chromosome band 12q24.11q24.23 results in apparent Noonan syndrome. Am J Med Genet A 146A:1042–1048 (2008).
167.
Sieburth DS, Sun Q, Han M: SUR-8, a conserved Ras-binding protein with leucine-rich repeats, positively regulates Ras-mediated signaling in C. elegans. Cell94:119–130 (1998).
168.
Silvius JR: Mechanisms of Ras protein targeting in mammalian cells. J Membr Biol 190:83–92 (2002).
169.
Singer ST, Hurst D, Addiego JE Jr: Bleeding disorders in Noonan syndrome: Three case reports and review of the literature. J Pediatr Hematol Oncol 19:130–134 (1997).
170.
Somerville J, Bonham-Carter RE: The heart in lentiginosis. Br Heart J 34:58–66 (1972).
171.
Sondermann H, Soisson SM, Boykevisch S, Yang SS, Bar-Sagi D, Kuriyan J: Structural analysis of autoinhibition in the Ras activator Son of sevenless. Cell 119:393–405 (2004).
172.
Sondermann H, Nagar B, Bar-Sagi D, Kuriyan J: Computational docking and solution X-ray scattering predict a membrane-interacting role for the histone domain of the Ras activator Son of sevenless. Proc Natl Acad Sci USA 102:16632–16637 (2005).
173.
Spurlock G, Bennett E, Chuzhanova N, Thomas N, Jim HP, et al: SPRED1 mutations (Legius syndrome): another clinically useful genotype for dissecting the neurofibromatosis type 1 phenotype. J Med Genet 46:431–437 (2009).
174.
Swanson KD, Winter JM, Reis M, Bentires-Alj M, Greulich H, et al: SOS1 mutations are rare in human malignancies: implications for Noonan syndrome patients. Genes Chromosomes Cancer 47:253–259 (2008).
175.
Tanaka K, Sato A, Naito T, Kuramochi K, Itabashi H, Takemura Y: Noonan syndrome presenting growth hormone neurosecretory dysfunction. Intern Med 31:908–911 (1992).
176.
Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, et al: Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29:465–468 (2001).
177.
Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, et al: PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 70:1555–1563 (2002).
178.
Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, et al: Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34:148–150 (2003).
179.
Tartaglia M, Martinelli S, Cazzaniga G, Cordeddu V, Iavarone I, et al: Genetic evidence for lineage- and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 104:307–313 (2004a).
180.
Tartaglia M, Niemeyer CM, Shannon KM, Loh ML: SHP-2 and myeloid malignancies. Curr Opin Hematol 11:44–50 (2004b).
181.
Tartaglia M, Martinelli S, Iavarone I, Cazzaniga G, Spinelli M, et al: Somatic PTPN11 mutations in childhood acute myeloid leukaemia. Br J Haematol 129:333–339 (2005).
182.
Tartaglia M, Martinelli S, Stella L, Bocchinfuso G, Flex E, et al: Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet 78:279–290 (2006).
183.
Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, et al: Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 39:75–79 (2007).
184.
Thiel C, Wilken M, Zenker M, Sticht H, Fahsold R, et al: Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome. Am J Med Genet A 149A:1263–1267 (2009).
185.
van der Burgt I: Noonan syndrome. Orphanet J Rare Dis 2:4 (2007).
186.
van der Burgt I, Brunner H: Genetic heterogeneity in Noonan syndrome: evidence for an autosomal recessive form. Am J Med Genet 94:46–51 (2000).
187.
van der Burgt I, Berends E, Lommen E, van Beersum S, Hamel B, Mariman E: Clinical and molecular studies in a large Dutch family with Noonan syndrome. Am J Med Genet 53:187–191 (1994).
188.
van der Burgt I, Kupsky W, Stassou S, Nadroo A, Barroso C, et al: Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation. J Med Genet 44:459–462 (2007).
189.
Verhoeven W, Wingbermühle E, Egger J, Van der Burgt I, Tuinier S: Noonan syndrome: psychological and psychiatric aspects. Am J Med Genet A 146A:191–196 (2008).
190.
Voron DA, Hatfield HH, Kalkhoff MD: Multiple lentigines syndrome: case report and review of the literature. Am J Med 60:447–456 (1976).
191.
Walter M, Clark SG, Levinson AD: The oncogenic activation of human p21ras by a novel mechanism. Science 233:649–652 (1986).
192.
Wang DZ, Hammond VE, Abud HE, Bertoncello I, McAvoy JW, Bowtell DD: Mutation in Sos1 dominantly enhances a weak allele of the EGFR, demonstrating a requirement for Sos1 in EGFR signaling and development. Genes Dev 11:309–320 (1997).
193.
Wellbrock C, Karasarides M, Marais R: The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5:875–885 (2004).
194.
Wennerberg K, Rossman KL, Der CJ: The Ras superfamily at a glance. J Cell Sci 118:843–846 (2005).
195.
Wieczorek D, Majewski F, Gillessen-Kaesbach G: Cardio-facio-cutaneous (CFC) syndrome – a distinct entity? Report of three patients demonstrating the diagnostic difficulties in delineation of CFC syndrome. Clin Genet 52:37–46 (1997).
196.
Witt DR, Keena BA, Hall JG, Allanson JE: Growth curves for height in Noonan syndrome. Clin Genet 30:150–153 (1986).
197.
Wojnowski L, Zimmer AM, Beck TW, Hahn H, Bernal R, et al: Endothelial apoptosis in Braf-deficient mice. Nat Genet 16:293–297 (1997).
198.
Xu D, Qu CK: Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci 13:4925–4932 (2008).
199.
Xu R, Yu Y, Zheng S, Zhao X, Dong Q, et al: Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. Blood 106:3142–3149 (2005).
200.
Zampino G, Mastroiacovo P, Ricci R, Zollino M, Segni G, et al: Costello syndrome: further clinical delineation, natural history, genetic definition, and nosology. Am J Med Genet 47:176–183 (1993).
201.
Zampino G, Pantaleoni F, Carta C, Cobellis G, Vasta I, et al: Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Hum Mutat 28:265–272 (2007).
202.
Zenker M, Buheitel G, Rauch R, Koenig R, Bosse K, et al: Genotype-phenotype correlations in Noonan syndrome. J Pediatr 144:368–374 (2004).
203.
Zenker M, Horn D, Wieczorek D, Allanson J, Pauli S, et al: SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome. J Med Genet 44:651–656 (2007a).
204.
Zenker M, Lehmann K, Schulz AL, Barth H, Hansmann D, et al: Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 44:131–135 (2007b).
205.
Zheng CF, Guan KL: Properties of MEKs: the kinases that phosphorylate and activate the extracellular signal-regulated kinases. J Biol Chem 268:23933–23939 (1993).
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.